Related Experiment Video
Updated: Aug 1, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Dissecting how ALS-associated D290V mutation enhances pathogenic aggregation of hnRNPA2286-291 peptides: Dynamics and
Yuan Tan1, Yujie Chen1, Xianshi Liu1
1State Key Laboratory of Surface Physics, and Key Laboratory for Computational Physical Sciences (Ministry of Education), Department of Physics, Fudan University, Shanghai 200438, People's Republic of China.
Abstract:
The aggregation of RNA binding proteins, including hnRNPA1/2, TDP-43 and FUS, is heavily implicated in causing or increasing disease risk for a series of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A recent experimental study demonstrated that an ALS-related D290V mutation in the low complexity domain (LCD) of hnRNPA2 can enhance the aggregation propensity of wild type (WT) hnRNPA2286-291 peptide. However, the underlying molecular mechanisms remain elusive. Herein, we investigated effects of D290V mutation on aggregation dynamics of hnRNPA2286-291 peptide and the conformational ensemble of hnRNPA2286-291 oligomers by performing all-atom molecular dynamic and replica-exchange molecular dynamic simulations. Our simulations demonstrate that D290V mutation greatly reduces the dynamics of hnRNPA2286-291 peptide and that D290V oligomers possess higher compactness and β-sheet content than WT, indicative of mutation-enhanced aggregation capability. Specifically, D290V mutation strengthens inter-peptide hydrophobic, main-chain hydrogen bonding and side-chain aromatic stacking interactions. Those interactions collectively lead to the enhancement of aggregation capability of hnRNPA2286-291 peptides. Overall, our study provides insights into the dynamics and thermodynamic mechanisms underlying D290V-induced disease-causing aggregation of hnRNPA2286-291, which could contribute to better understanding of the transitions from reversible condensates to irreversible pathogenic aggregates of hnRNPA2 LCD in ALS-related diseases.
Insights
The D290V mutation in hnRNPA2 enhances peptide aggregation, a key factor in neurodegenerative diseases like ALS. This mutation increases peptide compactness and beta-sheet content, promoting disease-causing protein aggregation.
Area of Science:
- Biochemistry
- Neuroscience
- Computational Biology
Background:
- RNA binding proteins, including hnRNPA1/2, TDP-43, and FUS, are implicated in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS).
- An ALS-related D290V mutation in the low complexity domain (LCD) of hnRNPA2 enhances the aggregation of hnRNPA2 peptides, but the molecular mechanisms are unclear.
Purpose of the Study:
- To investigate the molecular mechanisms by which the D290V mutation affects the aggregation dynamics and conformational ensemble of hnRNPA2 peptides.
- To elucidate the role of specific molecular interactions in mediating the enhanced aggregation propensity of the D290V mutant.
Main Methods:
- All-atom molecular dynamic (MD) simulations.
- Replica-exchange molecular dynamic (REMD) simulations were employed to explore the conformational landscape of hnRNPA2 peptides.
Main Results:
- The D290V mutation significantly reduces the dynamics of the hnRNPA2 peptide.
- Oligomers formed by the D290V mutant exhibit increased compactness and higher beta-sheet content compared to wild-type (WT) oligomers.
- The D290V mutation strengthens inter-peptide hydrophobic interactions, main-chain hydrogen bonding, and side-chain aromatic stacking.
Conclusions:
- The D290V mutation enhances the aggregation capability of hnRNPA2 peptides through increased compactness and specific intermolecular interactions.
- These findings provide insights into the dynamics and thermodynamic mechanisms of D290V-induced aggregation in hnRNPA2 LCD.
- Understanding these mechanisms is crucial for comprehending the transition of hnRNPA2 LCD from reversible condensates to irreversible pathogenic aggregates in ALS-related diseases.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Export of Misfolded Proteins out of the ER
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...

